Clinical significance of ductal carcinoma in situ of the breast

Seminars in Breast Disease

Volumn 3, Issue 1, 2000, Pages 8-13

  Feig, S A ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOPSY; BREAST CARCINOMA; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CARCINOMA IN SITU; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTECTOMY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; UNITED STATES;

EID: 0034502543     PISSN: 10924450     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Medical audit of a rapid-throughput mammography screening practice: Methodology and results of 27,114 examinations
2. Positive predictive value of breast biopsy performed as a result of mammography: There is no abrupt change at age 50 years
3. Comparison of the relative incidence of impalpable invasive breast carcinoma and ductal carcinoma in situ in patients older and younger than 50 years of age
4. Non-invasive breast cancer. The dilemma of the 1990's
5. Radiology of minimal breast cancer
6. Twenty-year follow-up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project
7. Risk factors for breast cancer in women with proliferative breast disease
8. Mammographically detected ductal carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence
9. Ductal carcinoma in situ of the breast: Heterogeneity of individual lesions
10. Early phases in the development of breast cancer
11. The study of mammary carcinoma by mammography and whole organ sectioning
12. The use of pathologic features in selecting the extent of surgical resection necessary for breast cancer patients treated by primary radiation therapy
13. Why question screening mammography for women in their forties?
14. Incidence and treatment for ductal carcinoma in situ of the breast
15. Variation of benefits and harms of breast cancer screening with age
16. How to prevent invasive breast cancer: Detect and excise ductal carcinoma in situ
17. Occult breast cancer: Prevalence and radiographic detectability
18. Precancerous and cancerous breast lesions during lifetime and at autopsy: A study of 83 women
19. Breast cancer and atypia among young and middle-aged women: A study of 110 medicolegal autopsies
20. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer
21. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women
22. The prevalence of carcinoma in situ in normal and cancer associated breasts
23. On the origin and progression of ductal carcinoma in the human breast
24. Mammary duct proliferation in the elderly
25. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammoqraphy: A dilemma
26. Ductal carcinoma in situ of the breast. Understanding the misunderstood stepchild
27. Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone
28. Intraductal carcinoma of the breast: Follow-up after biopsy only
29. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy
30. Iutraductal carcinoma of the breast (208 cases): Clinical factors influencing treatment choice
31. Subclinical ductal carcinoma in situ of the breast. Treatment by local excision and surveillance alone
32. Ductal carcinoma in situ of the breast
33. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer
34. Bilateral primary breast cancers: A prospective clinicopathologic study
35. Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study
36. Family history and bilateral primary breast cancer
37. Risk factors for ductal carcinoma in situ
38. Ductal carcinoma in situ of the breast
39. Preinvasive intraductal carcinoma of the breast
40. Intraductal "noninfiltrating" carcinoma of the breast
41. Ductal carcinoma in situ: Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases and short-term treatment failures
42. Heterogeneity of intraductal carcinoma of the breast
43. Invasive ductal carcinoma accompanied by ductal carcinoma in situ (DCIS): Comparison of DCIS grade with grade of invasive component
44. Prognostic factors of breast neoplasms detected on screening by mammography and physical examination
45. Relationship between mammographic screening intervals and size and histology of ductal carcinoma in situ
46. Estimation of currently attainable benefit from mammographic screening of women aged 40-49 years
47. A Markov chain method to estimate the tumor progression rate from preclinical to clinical phase, sensitivity and positive predictive value for mammography in breast cancer screening
48. Markov chain models for progression of breast cancer. Part 1: Tumor attributes and the preclinical screen-detectable phase
49. The natural history of breast cancer. What have we learned from screening?
50. Evidence on screening for breast cancer from a randomized trial
51. Survival experience in the Breast Cancer Detection Demonstration Project
52. New Swedish breast cancer detection results for women aged 40-49